Agorafobia
Published on September 10, 2026
Risk Factors
Female sex (2:1 ratio), late adolescence to mid-30s onset, history of panic disorder, prior traumatic or stressful life events, family history of anxiety disorders, dependent personality traits
Etiology
Multifactorial: genetic predisposition, dysregulation of the fear-conditioning circuitry (amygdala-hippocampal-prefrontal axis), learned avoidance behavior reinforced by anxiety reduction, cognitive catastrophizing about being trapped or helpless
Presentation
Progressive avoidance of public spaces, crowds, traveling alone, or leaving the house; the patient reports intense anxiety or panic when exposed to these situations and may become completely housebound
Classic Exam
No primary physical findings; during acute anxiety episodes: tachycardia, diaphoresis, tremor, hyperventilation; the mental status exam reveals anxious affect, intact cognition, no psychotic features, no obsessional content
Diagnostics
Clinical diagnosis based on PPDGJ-III criteria; no laboratory or imaging test confirms the diagnosis; screening tools (e.g., Mobility Inventory for Agoraphobia) support severity grading; thyroid function tests ordered to exclude hyperthyroidism as a mimic
Management
First-line: SSRI (sertraline or escitalopram) combined with cognitive-behavioral therapy (CBT) with graded exposure; benzodiazepines for short-term bridging only; long-term relapse prevention with CBT maintenance
01Pathophysiology
Agoraphobia arises from a dysfunction in the brain's threat-detection and avoidance circuitry. The amygdala becomes hyperresponsive to environmental cues associated with perceived danger, such as crowded spaces, open areas, or situations where escape is perceived as difficult. This triggers an exaggerated autonomic fight-or-flight response mediated by the sympathetic nervous system, producing tachycardia, hyperventilation, sweating, and a subjective sense of impending doom.
The critical mechanism that sustains and worsens agoraphobia is negative reinforcement through avoidance. When a patient avoids a feared situation (e.g., a crowded market), the anxiety drops immediately. This relief powerfully reinforces the avoidance behavior, making the patient increasingly likely to avoid the same situation in the future. Over time, the range of avoided situations expands through a process of stimulus generalization: a patient who initially avoided only crowded malls may begin to avoid all public transportation, then all outdoor spaces, and eventually refuse to leave the house altogether.
This is why the PPDGJ-III criterion (c) emphasizes that avoidance must be a prominent feature of the presentation and that the patient may become "housebound". The avoidance is not a secondary behavior; it is the defining feature that distinguishes agoraphobia from simple anxiety episodes.
The prefrontal cortex, which normally provides top-down inhibitory regulation of the amygdala ("this situation is safe, the fear is excessive"), fails to adequately suppress the fear response. Cognitive-behavioral models describe this as catastrophic misinterpretation: the patient cognitively interprets benign physical sensations (mild tachycardia, dizziness) as evidence of a dangerous situation, which feeds back into the anxiety loop.
A key point for exam purposes: the PPDGJ-III requires that the psychological, behavioral, or autonomic symptoms must be the primary manifestation of anxiety and not secondary to other psychiatric symptoms such as delusions (waham) or obsessive thoughts (pikiran obsesif). This directly tests your ability to distinguish primary anxiety disorders from anxiety that occurs in the context of psychosis or OCD.
02Classification and Clinical Manifestation
PPDGJ-III Diagnostic Criteria (All Three Must Be Met)
Criterion | Requirement | Clinical Implication |
|---|---|---|
Primary anxiety manifestation | Psychological, behavioral, or autonomic symptoms must be the primary expression of anxiety, not secondary to delusions, obsessions, or other psychiatric phenomena | Rules out anxiety secondary to psychotic disorders or OCD |
Situational restriction | Anxiety must occur in association with at least two of the following: crowds/gatherings, public places, traveling away from home, traveling alone | Differentiates agoraphobia from a single-situation phobia (e.g., social phobia or claustrophobia) |
Prominent avoidance | Avoidance of phobic situations is or has become a dominant symptom; patient may become "housebound" | Establishes severity and functional impairment |
Subtypes and Severity Spectrum
Severity | Behavioral Pattern | Functional Impact |
|---|---|---|
Mild | Avoids one or two situations (e.g., crowded shopping centers) but can still travel with a companion | Minimal occupational impairment; social life restricted |
Moderate | Avoids most public places; leaves home only when accompanied; increasing dependence on others | Significant occupational and social impairment |
Severe (Housebound) | Refuses to leave the house; panic attacks at the thought of going outside; complete social isolation | Total functional disability |
Agoraphobia With vs. Without Panic Disorder
Feature | Agoraphobia with Panic Disorder | Agoraphobia without Panic Disorder |
|---|---|---|
Panic attacks | Recurrent, unexpected panic attacks precede the development of avoidance | No history of full-blown panic attacks |
Core fear | Fear of having another panic attack in a situation where escape is difficult | Fear of the situation itself (e.g., being in a crowd) or of developing embarrassing or incapacitating symptoms |
Onset pattern | Avoidance develops after repeated panic episodes | Avoidance may develop gradually without a clear panic trigger |
Exam relevance | More commonly tested; the vignette will describe discrete panic episodes followed by progressive avoidance | Less commonly tested; the vignette will describe chronic, gradually worsening avoidance without dramatic panic episodes |
03Diagnostic Workup
Test | Purpose | Expected Finding |
|---|---|---|
Clinical interview (Best Initial and Confirmatory Test) | Structured psychiatric assessment against PPDGJ-III criteria | Meets all three criteria (a), (b), and (c) as described above |
Thyroid function tests (TSH, free T4) | Exclude hyperthyroidism as a cause of autonomic symptoms | Normal in agoraphobia; elevated free T4 and suppressed TSH suggest thyrotoxicosis |
Complete blood count | Exclude anemia as a cause of dizziness and tachycardia | Normal |
Electrocardiogram | Rule out arrhythmia in patients presenting with palpitations | Normal sinus rhythm; may show sinus tachycardia during acute anxiety |
Urine toxicology | Exclude stimulant use (amphetamines, cocaine, caffeine excess) | Negative |
Screening questionnaire (e.g., Panic and Agoraphobia Scale) | Quantify symptom severity and monitor treatment response | Elevated scores correlating with avoidance severity |
Agoraphobia is a clinical diagnosis. There is no laboratory test or imaging study that confirms it. The diagnostic workup serves two purposes: (1) to systematically verify that the patient meets PPDGJ-III criteria, and (2) to exclude medical conditions that mimic anxiety-related autonomic symptoms.
The best initial step when a patient presents with progressive avoidance of public places and anxiety symptoms is a thorough psychiatric interview. You are looking for three things: confirmation that the autonomic and psychological symptoms are the primary manifestation of anxiety (not secondary to psychosis or OCD), that the anxiety is situationally linked to at least two of the four listed scenarios, and that avoidance behavior is prominent.
After the clinical assessment, order a basic medical workup to rule out organic causes. Hyperthyroidism is the most important medical mimic, as it produces tachycardia, tremor, diaphoresis, and anxiety. Pheochromocytoma is rare but classically tested as a cause of episodic autonomic surges. Cardiac arrhythmias can present with palpitations and a sense of impending doom. Stimulant intoxication (cocaine, amphetamines) can produce acute panic-like episodes.
On an exam, if the vignette describes a patient with classic agoraphobic avoidance, normal vital signs between episodes, and no red flags (weight loss, exophthalmos, hypertension), the answer is clinical diagnosis based on criteria. Do not order unnecessary imaging.
04Management and Treatment
Phase | Intervention | Details |
|---|---|---|
First-line pharmacotherapy | SSRI | Sertraline 50 mg/day (titrate to 200 mg/day) or escitalopram 10 mg/day (titrate to 20 mg/day); onset of therapeutic effect in 4 to 6 weeks |
First-line psychotherapy | CBT with graded in vivo exposure | 12 to 16 sessions; systematic desensitization to feared situations; cognitive restructuring of catastrophic thoughts |
Short-term bridging | Benzodiazepine (e.g., alprazolam 0.25 to 0.5 mg TID) | Used only during the first 2 to 4 weeks while waiting for SSRI onset; taper and discontinue once SSRI is effective |
Second-line pharmacotherapy | SNRI (venlafaxine XR 75 to 225 mg/day) or clomipramine (25 to 150 mg/day) | For patients who fail or cannot tolerate SSRIs |
Maintenance | Continue SSRI for at least 12 months after remission; ongoing CBT booster sessions | Reduces relapse risk, which is high if medication is stopped prematurely |
Treatment-resistant cases | Combination of SSRI + CBT + augmentation with buspirone or low-dose atypical antipsychotic | Referral to a psychiatrist for reassessment and consideration of alternative diagnoses |
The most testable point in management is the combination of pharmacotherapy and psychotherapy. Neither alone is as effective as both together. On an exam, if the question asks for the single best initial treatment, the answer is typically SSRI plus CBT with exposure therapy.
Graded exposure is the cornerstone of CBT for agoraphobia. The therapist constructs a fear hierarchy with the patient (e.g., step 1: standing at the front door, step 2: walking to the end of the street, step 3: visiting a small shop, step 4: riding public transportation). The patient systematically works through these steps, learning through repeated experience that the feared catastrophe does not occur. This directly reverses the negative reinforcement cycle described in the pathophysiology section.
Benzodiazepines are a frequent exam trap. They provide rapid symptom relief, which makes them tempting as a first-line agent. However, they carry risks of dependence, tolerance, and rebound anxiety, and they interfere with the extinction learning that makes CBT effective. The correct use is short-term bridging only while waiting for the SSRI to reach therapeutic effect.
Contraindications and adjustments:
In pregnancy, SSRIs (particularly sertraline) remain first-line as they have the most reassuring safety data. Benzodiazepines are avoided due to risks of neonatal sedation and withdrawal. Paroxetine is contraindicated in the first trimester due to cardiac teratogenicity.
In elderly patients, start SSRIs at half the standard dose and titrate slowly. Benzodiazepines are particularly dangerous due to fall risk, cognitive impairment, and paradoxical agitation.
In patients with comorbid substance use disorder, avoid benzodiazepines entirely. Emphasize CBT and SSRIs.
05Differential Diagnosis and Distractors
Differential | Why It Looks Similar | Key Discriminator |
|---|---|---|
Social phobia (social anxiety disorder) | Both involve avoidance of situations with other people | In social phobia, the fear is of being judged or embarrassed; in agoraphobia, the fear is of being trapped or unable to escape. The agoraphobic patient fears the situation, not the social evaluation. |
Panic disorder without agoraphobia | Both involve recurrent panic attacks with autonomic symptoms | In panic disorder alone, the patient does not develop progressive avoidance of situations. The vignette will describe panic attacks occurring in varied settings without a pattern of avoidance or housebound behavior. |
Generalized anxiety disorder (GAD) | Both involve chronic anxiety and autonomic symptoms | GAD features persistent, free-floating worry about multiple life domains (work, health, finances), not anxiety restricted to identifiable phobic situations. There is no prominent avoidance behavior. |
OCD with avoidance | Both may feature avoidance of situations | In OCD, the avoidance is driven by obsessional content (e.g., avoiding doorknobs due to contamination fears). Per PPDGJ-III criterion (a), agoraphobia requires that anxiety is the primary symptom, not secondary to obsessions. |
Delusional disorder with persecutory delusions | Both may result in the patient refusing to leave home | In delusional disorder, the patient avoids going out because of a fixed, false belief (e.g., "people are following me"), not because of anxiety about crowds or open spaces. Again, criterion (a) directly addresses this. |
Major depressive disorder with psychomotor retardation | Both may result in the patient being homebound | In depression, the patient stays home due to anhedonia, fatigue, and lack of motivation, not due to fear of being in public. The depressed patient does not describe anxiety about going outside; they simply have no desire or energy to do so. |
Hyperthyroidism | Produces tachycardia, tremor, sweating, and anxiety | Look for weight loss, heat intolerance, exophthalmos, and elevated free T4. The symptoms are constant, not situationally triggered. |
06Traps and High-Yield Pearls
The single most common way students lose points on agoraphobia questions is by confusing it with panic disorder or social phobia. Test-writers exploit this overlap deliberately. The distinguishing feature is always the pattern of avoidance: agoraphobia requires progressive avoidance of at least two situational categories (crowds, public places, leaving home, traveling alone) with the avoidance itself becoming a dominant, disabling symptom. If the vignette describes a patient who has panic attacks but continues to function in public without avoidance, the answer is panic disorder, not agoraphobia.
The second trap involves criterion (a) from PPDGJ-III. A vignette may describe a patient who avoids leaving the house, but the underlying reason is a paranoid delusion or obsessional fear of contamination. Students who focus only on the avoidance behavior and skip the requirement for primary anxiety will select agoraphobia incorrectly. Always ask: "Is the anxiety the primary driver, or is it secondary to another psychiatric process?"
The third common error is selecting benzodiazepines as first-line treatment. The vignette may emphasize the severity of the patient's distress, making rapid relief seem like the priority. The correct answer is always SSRI plus CBT. Benzodiazepines are acceptable only as a short-term bridge.
Finally, remember the PPDGJ-III "two-situation rule." If the patient's fear is limited to only one situation (e.g., only afraid of enclosed spaces), the diagnosis is a different phobia, not agoraphobia. The requirement for at least two of the four listed situations is a testable criterion that separates agoraphobia from other phobic disorders.